BTTX insider filings

Better Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-02-13. Screen BTTX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for BTTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Better Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2024-02-134PERRY DAVID P — Executive Chairman, Director, 10% owner
David P. Perry 2015 Trust — 10% owner
Grant/award (A): 839,895 @ $0.19EDGAR
2024-01-104PERRY DAVID P — Executive Chairman, Director, 10% ownerGrant/award (A): 1,471,453 @ $0.17EDGAR
2023-12-204Wynholds Kristin — Chief Product OfficerGrant/award (A): 25,362 @ $0EDGAR
2023-12-204Miller Leslie A. — Principal Accounting OfficerGrant/award (A): 3,587 @ $0EDGAR
2023-12-204Berman Mark A. — Chief Medical OfficerGrant/award (A): 25,362 @ $0EDGAR
2023-12-204Armanino Andrew J. — DirectorGrant/award (A): 3,750 @ $0EDGAR
2023-12-204Granger Elder — DirectorGrant/award (A): 3,750 @ $0EDGAR
2023-12-204Parker Geoffrey M. — DirectorGrant/award (A): 3,750 @ $0EDGAR
2023-12-204Carmona Richard H — DirectorGrant/award (A): 3,750 @ $0EDGAR
2023-12-204KARBE FRANK — Chief Executive Officer, DirectorGrant/award (A): 62,500 @ $0EDGAR
2023-12-204PERRY DAVID P — Executive Chairman, Director, 10% ownerGrant/award (A): 3,750 @ $0EDGAR
2023-12-204LAVIZZO-MOUREY RISA J — DirectorGrant/award (A): 3,750 @ $0EDGAR
2023-07-314Berman Mark A. — Chief Medical OfficerPurchase (P): 54,802 @ $0.73EDGAR
2023-07-314Armanino Andrew J. — DirectorPurchase (P): 274,010 @ $0.73EDGAR
2023-07-314Granger Elder — DirectorPurchase (P): 34,251 @ $0.73EDGAR
2023-07-314Parker Geoffrey M. — DirectorPurchase (P): 685,025 @ $0.73EDGAR
2023-07-314KARBE FRANK — Chief Executive Officer, DirectorPurchase (P): 137,005 @ $0.73EDGAR
2023-07-314PERRY DAVID P — Executive Chairman, Director, 10% ownerPurchase (P): 1,233,045 @ $0.73EDGAR
2023-06-094Armanino Andrew J. — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2023-06-094Granger Elder — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2023-06-094Parker Geoffrey M. — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2023-06-094Carmona Richard H — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2023-06-094PERRY DAVID P — Executive Chairman, Director, 10% ownerGrant/award (A): 15,000 (derivative) @ $0EDGAR
2023-06-094LAVIZZO-MOUREY RISA J — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2023-05-184Granger Elder — DirectorPurchase (P): 600 @ $0.87EDGAR
2023-04-214Heinen Mark — Chief Financial OfficerGrant/award (A): 54,000 @ $0 · Grant/award (A): 28,550 (derivative) @ $0EDGAR
2023-04-214Wynholds Kristin — Chief Product OfficerGrant/award (A): 101,450 @ $0 · Grant/award (A): 101,450 (derivative) @ $0EDGAR
2023-04-214Berman Mark A. — Chief Medical OfficerGrant/award (A): 101,450 @ $0 · Grant/award (A): 101,450 (derivative) @ $0EDGAR
2023-04-124Armanino Andrew J. — DirectorPurchase (P): 303,030 @ $0.82EDGAR
2023-04-124Parker Geoffrey M. — DirectorPurchase (P): 303,030 @ $0.82EDGAR
2023-04-124KARBE FRANK — See Remarks, DirectorPurchase (P): 242,424 @ $0.82EDGAR
2023-04-124PERRY DAVID P — See Remarks, Director, 10% owner
David P. Perry 2015 Trust — 10% owner
Purchase (P): 1,333,333 @ $0.82 · Purchase (P): 3,636,364 @ $0.82EDGAR
2022-12-024Wynholds Kristin — Chief Product OfficerGrant/award (A): 5,023 @ $1.54 · Grant/award (A): 3,781 @ $1.24EDGAR
2022-12-024Heinen Mark — See RemarksGrant/award (A): 15,723 @ $1.24EDGAR
2022-09-194PERRY DAVID P — See Remarks, Director, 10% owner
David P. Perry 2015 Trust — 10% owner
Purchase (P): 10,844 @ $1.99 · Purchase (P): 39,156 @ $2.07EDGAR
2022-09-154KARBE FRANK — See Remarks, DirectorPurchase (P): 50,000 @ $2.09EDGAR
2022-09-144Heinen Mark — See RemarksPurchase (P): 23,868 @ $1.94 · Purchase (P): 26,132 @ $1.94EDGAR
2022-07-074KARBE FRANK — See Remarks, DirectorGrant/award (A): 472,200 (derivative) @ $0EDGAR
2022-06-284Heinen Mark — See RemarksPurchase (P): 2,280.61 @ $1.75EDGAR
2022-06-164Armanino Andrew J. — DirectorPurchase (P): 15,000 @ $1.39EDGAR
2022-06-144Parker Geoffrey M. — DirectorPurchase (P): 25,000 @ $1.45EDGAR
2022-06-104Heinen Mark — See RemarksPurchase (P): 5,000 @ $1.56EDGAR
2022-06-104Liu Suying — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-104Armanino Andrew J. — DirectorPurchase (P): 25,000 @ $1.65 · Grant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-104Granger Elder — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-104Parker Geoffrey M. — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-104Carmona Richard H — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-104PERRY DAVID P — See Remarks, Director, 10% ownerGrant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-104LAVIZZO-MOUREY RISA J — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-014Zamirowski Justin — Chief Commercial OfficerOption exercise (M): 1,677 @ $0.50 · Option exercise (M): 1,677 (derivative) @ $0EDGAR

Recent 8-K events — Better Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-03-218-K2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementEDGAR
2024-03-158-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2024-03-148-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-118-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-03-048-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-01-088-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2023-12-188-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-12-138-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2023-11-308-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
EDGAR
2023-11-208-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=BTTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs